Pomalyst (pomalidomide) is a prescription drug that’s used to treat multiple myeloma in adults ... Pomalyst is not chemotherapy. It is a type of immunotherapy called an immunomodulating agent.

Over the past two decades the paradigm of multiple myeloma therapy has changed dramatically from conventional chemotherapy and ... and on the time to relapse and drug refractoriness.

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Multiple myeloma is currently not curable, but we can manage the disease effectively for years. For active myeloma, treatment may include chemotherapy, proteasome inhibitors, immune-modifying drugs or ...

S Lional is supported by the Richard and Annelly Deets Fund for Multiple Myeloma and acts as a consultant ... Sequential therapy refers to treatment with drug regimens administered one after ...

2 Today, treatment for multiple myeloma often involves an intensive combination of chemotherapy, steroids, immunomodulatory drugs, and bone marrow transplants to slow down this multiplication and ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

Specialists of Samara State Medical University (SamSMU) together with the pharmaceutical company Euroservice plan to develop a drug for the treatment of multiple myeloma using natural cord blood ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

Multiple Genetic Abnormalities Lead to Poor Prognosis Around 5900 people are diagnosed with myeloma each year in the UK. Standard treatments include targeted drugs, chemotherapy, and stem cell ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...